PL376452A1 - Zastosowanie związków typu heterocyklicznej aminyjako środków neuroochronnych - Google Patents

Zastosowanie związków typu heterocyklicznej aminyjako środków neuroochronnych

Info

Publication number
PL376452A1
PL376452A1 PL03376452A PL37645203A PL376452A1 PL 376452 A1 PL376452 A1 PL 376452A1 PL 03376452 A PL03376452 A PL 03376452A PL 37645203 A PL37645203 A PL 37645203A PL 376452 A1 PL376452 A1 PL 376452A1
Authority
PL
Poland
Prior art keywords
type compounds
heterocyclic amine
neuroprotective agents
neuroprotective
agents
Prior art date
Application number
PL03376452A
Other languages
English (en)
Inventor
Haiyan Wu
Jo Ann Oostveen
Vimala Hiralal Sethy
Edward Dallas Hall
Robert Bradford Mccall
Original Assignee
Pharmacia & Upjohn Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company Llc filed Critical Pharmacia & Upjohn Company Llc
Publication of PL376452A1 publication Critical patent/PL376452A1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL03376452A 2002-10-25 2003-10-13 Zastosowanie związków typu heterocyklicznej aminyjako środków neuroochronnych PL376452A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42135202P 2002-10-25 2002-10-25

Publications (1)

Publication Number Publication Date
PL376452A1 true PL376452A1 (pl) 2005-12-27

Family

ID=32176704

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03376452A PL376452A1 (pl) 2002-10-25 2003-10-13 Zastosowanie związków typu heterocyklicznej aminyjako środków neuroochronnych

Country Status (11)

Country Link
US (1) US20040142937A1 (pl)
EP (1) EP1569649A2 (pl)
JP (1) JP2006505580A (pl)
KR (1) KR20050057671A (pl)
CN (1) CN1728998A (pl)
AU (1) AU2003267769A1 (pl)
BR (1) BR0315517A (pl)
CA (1) CA2502729A1 (pl)
MX (1) MXPA05004297A (pl)
PL (1) PL376452A1 (pl)
WO (1) WO2004037971A2 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0613430A2 (pt) 2005-07-13 2011-01-11 Hoffmann La Roche compostos derivados de benzimidazol, uso dos mesmos, método para a preparação destes e composição farmacêutica
KR102343165B1 (ko) * 2020-01-08 2021-12-24 숙명여자대학교산학협력단 생물학적 시료를 이용한 대장암 발암물질 노출 여부 진단방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2067744T3 (es) * 1989-06-09 1995-04-01 Upjohn Co Aminas heterociclicas con actividad sobre el sistema nervioso central.
US5273975A (en) * 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
DK0724584T3 (da) * 1993-07-27 1998-05-25 Upjohn Co Heterocycliske aminer med CNS-virkning
US6156777A (en) * 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
US6451837B1 (en) * 1999-09-01 2002-09-17 Andrius Baskys Neuroprotective effects of mitogen-activated protein kinase (MAPK) cascade inhibitors
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
DE60310039T2 (de) * 2002-02-07 2007-04-05 Pharmacia Corp. Pharmazeutische Tabletten

Also Published As

Publication number Publication date
EP1569649A2 (en) 2005-09-07
WO2004037971A3 (en) 2005-05-26
BR0315517A (pt) 2005-08-09
CA2502729A1 (en) 2004-05-06
US20040142937A1 (en) 2004-07-22
KR20050057671A (ko) 2005-06-16
WO2004037971A2 (en) 2004-05-06
AU2003267769A1 (en) 2004-05-13
MXPA05004297A (es) 2005-08-03
CN1728998A (zh) 2006-02-01
JP2006505580A (ja) 2006-02-16

Similar Documents

Publication Publication Date Title
PL377087A1 (pl) Związki heterocykliczne
IL156595A0 (en) Therapeutic heterocyclic compounds
IL174375A0 (en) Novel heterocyclic compounds as hsp90-inhibitors
IL209082A0 (en) Fushed heterocyclic compounds
AU2003291310A8 (en) Fused heterocyclic compounds and use thereof
PL376575A1 (pl) Podstawione związki heterocykliczne oraz sposoby wykorzystania
GB0315870D0 (en) Heterocyclic derivatives
PL1651604T3 (pl) Związki N-´2-(2-pirydynylo)etylobenzamidy i ich zastosowanie jako środki grzybobójcze
GB0305150D0 (en) Use of therapeutic compounds
EP1476425A4 (en) Heterocyclic Aryl Sulphonamidocyclic Compounds
AU2003299100A1 (en) Pyrimidine compounds as therapeutic agents
GB0120818D0 (en) Heterocyclic compounds
GB2392618B (en) Compositions for therapeutic use
AU2003282510A8 (en) Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents
AU2003215150A8 (en) Therapeutic compounds
IS7833A (is) Efnasambönd með sameinaða heteróhringi
AU2003291642A8 (en) Pyrazoloazepine compounds as pharmaceutical agents
PL371539A1 (pl) Związki heterocykliczne wykazujące aktywność hamującą względem elastazy oraz ich związki pośrednie
PL376452A1 (pl) Zastosowanie związków typu heterocyklicznej aminyjako środków neuroochronnych
PL377708A1 (pl) Oksazole jako wzmacniacze mGluR1
EP1377289A4 (en) HETEROCYCLIC COMPOUNDS WITH THERAPEUTIC USE
AU2003291021A8 (en) Arylpyridine compounds
GB0208392D0 (en) Therapeutic compounds
GB0220962D0 (en) Heterocyclic derivatives
GB0202358D0 (en) Synthesis of fluorinating agents

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)